Combining RCTs and RWE studies to alter the regulatory approval process
26 February 2020
- Hybridisation of RCTs and RWE studies reinforce the benefits of both, while reducing the limitations of traditional study formats
- The potential of real-world data that provides adequate scientific evidence for regulatory decision-making is being realised
- Innovative study designs must be developed to unlock this potential
Click here to learn more
About SVMPharma
SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.
For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com
ref: FEB2020BR003